Daiichi Sankyo and biotechnology company ArQule have enrolled the first patient in a double-blinded, controlled, pivotal Phase III clinical study of its investigational selective inhibitor of MET, a receptor tyrosine kinase.
The MET inhibitor drug, tivantinib (ARQ 197), is designed to treat hepatocellular carcinoma (HCC), a disease leading to primary liver cancers.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The start of the pivotal study follows positive results from a Phase II study of tivantinib, which demonstrated improvements in overall survival and time to progression among MET-high patients.
The Phase III clinical study, METIV-HCC (MET-high patients with tivantinib in HCC), will enrol 300 patients with HCC who have received one or two prior systemic anti-cancer therapies.
The study, which includes previously treated patients with MET-high inoperable HCC, will randomise participants to receive treatment either with tivantinib or placebo.
The primary endpoint of the study is overall survival, while the secondary endpoint is progression-free survival (PFS).
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataDaiichi Sankyo senior executive officer and research and development global head Glenn Gormley said; "It is our hope that this late-stage study will confirm the positive results we saw in Phase II in time to progression (TTP) and overall survival (OS) observed in patients whose tumors were MET-high."
The partnership between the companies forms part of a licence, co-development and co-commercialisation agreement, signed in December 2008, for tivantinib in the US, Europe and South America.
An agreement was also reached with the US Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the pivotal Phase III trial.
